Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
PHVS Stock Chart & Stats
$21.12
-$0.46(-2.39%)
At close: 4:00 PM EST
$21.12
-$0.46(-2.39%)
Day’s Range― - ―
52-Week Range$11.51 - $26.33
Previous CloseN/A
Volume14.65K
Average Volume (3M)235.67K
Market Cap
$1.35B
Enterprise Value$728.99M
Total Cash (Recent Filing)$199.57M
Total Debt (Recent Filing)$634.15K
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Nov 05, 2025EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding64,055,640
10 Day Avg. Volume243,603
30 Day Avg. Volume235,673
Financial Highlights & Ratios
PEG Ratio1.31
Price to Book (P/B)3.73
Price to Sales (P/S)0.00
P/FCF Ratio-8.29
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.41
Forecast
1Y Price Target
$41.14Price Target Upside94.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentRobust randomized Phase 2 trial results show fast onset and durable attack suppression with meaningful quality-of-life gains for patients.
Financial StabilityPHVS guided to a cash runway into 1H27, indicating strong financial stability for the company.
Market PositioningPHVS is targeting a broad label for its drug to treat bradykinin-mediated angioedema, which could make it the only company with an oral option for both acute and prophylactic treatment.
Bears Say
Competitive LandscapeCompetitor KALV’s Ekterly has a head start as the only approved oral option for acute hereditary angioedema, which could limit the market opportunity for PHVS's drug.
Market ChallengesEntering a crowded market and off-label usage of approved players is common for the rarer subtypes, indicating the need for a strong commercial plan.
Prophylactic Market CompetitionOral competitor BCRX’s Orladeyo, approved in 2020, has a significant head start in the prophylactic market, which could limit PHVS's usage to treatment failures.
Pharvaris News
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $11.51 and its highest was $26.33 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is $1.35B.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Nov 05, 2025 which is in 16 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Aug 12, 2025. The company reported -$0.968 earnings per share for the quarter, missing the consensus estimate of -$0.893 by -$0.075.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate is -0.78.
How many shares outstanding does Pharvaris have?
Pharvaris has 64,055,640 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.968 in its last earnings report, missing expectations of -$0.893. Following the earnings report the stock price went up 1.612%.
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in PHVS
Pharvaris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.14 (94.79% Upside)
$41.14 (94.79% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.61%
12-Months-Change
Fundamentals
Return on Equity
-63.96%
Trailing 12-Months
Asset Growth
-34.69%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris (PHVS) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative oral therapies for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated diseases. The company operates within the biotechnology and pharmaceutical sectors, leveraging its proprietary small molecule chemistry platform to create novel treatments aimed at improving patient outcomes and quality of life.
PHVS Stock 12 Month Forecast
Average Price Target
$41.14
▲(94.79% Upside)
Technical Analysis
Ownership Overview
―
Insiders
7.41% Mutual Funds
59.18% Other Institutional Investors
32.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---